Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2011  |  Volume : 7  |  Issue : 3  |  Page : 331-335

Invasion is not an independent prognostic factor in high-grade glioma


1 Department of Radiation Oncology and Neurosurgery, New York University Langone Medical Center, New York, NY 10016, USA
2 Department of Radiation Oncology, New York University Langone Medical Center, New York, NY 10016, USA
3 Neuro-Oncology Atlantic Health System, Overlook Hospital, Summit, NJ 07901, USA
4 Department of Neurosurgery, New York University Langone Medical Center, New York, NY 10016, USA
5 Department of Biostatistics, New York University Langone Medical Center, New York, NY 10016, USA
6 Department of Neuropathology, New York University Langone Medical Center, New York, NY 10016, USA

Date of Web Publication2-Nov-2011

Correspondence Address:
Ashwatha Narayana
Department of Radiation Oncology, New York University Langone Medical Center, 550 1st Ave., New York, NY 10016
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.87039

Rights and Permissions
 > Abstract 

Purpose: The role of invasion as a prognostic factor in high-grade gliomas (HGG) remains controversial. An apparent increase in invasiveness following anti-angiogenic therapy makes this question clinically relevant. The goal of this study is to assess survival differences in patients with newly diagnosed HGG who present with diffuse invasive disease compared to those who did not, but went on to develop diffuse invasive disease following bevacizumab therapy.
Materials and Methods: Twenty-three patients presented as newly diagnosed diffuse invasive HGG. All patients underwent surgical resection with radiation therapy and temozolomide for one year. Progression-free survival (PFS) and overall survival (OS) were compared to a control of 58 patients with focal high-grade glioma who received similar therapy, but that included bevacizumab at 10 mg/kg given every two weeks.
Results: The patient characteristics were similar in each group. The median PFS and OS for invasive HGG patients were 6 and 13 months and for the focal HGG patients, 11 and 24 months, respectively (P=0.092 and P=0.071). In the subgroup of invasive HGG that showed significant angiogenesis, the median PFS and OS were 3 and 9 months, respectively. 56% of the focal HGG patients recurred as diffuse invasive relapse. For patients with focal HGG who recurred as invasive disease, the median PFS and OS were 9 and 21 months respectively.
Conclusions: Presence of diffuse invasive disease not accompanied by angiogenesis either prior to therapy or subsequent to anti-angiogenic therapy does not seem to have prognostic significance. However, invasion accompanied by angiogenesis in newly diagnosed HGG may confer a poor prognosis.

Keywords: Angiogenesis, bevacizumab, high-grade glioma, invasion, multifocal glioma


How to cite this article:
Narayana A, Perretta D, Kunnakkat S, Gruber D, Golfinos J, Parker E, Medabalmi P, Zagzag D, Pat Eagan R N, Gruber M. Invasion is not an independent prognostic factor in high-grade glioma. J Can Res Ther 2011;7:331-5

How to cite this URL:
Narayana A, Perretta D, Kunnakkat S, Gruber D, Golfinos J, Parker E, Medabalmi P, Zagzag D, Pat Eagan R N, Gruber M. Invasion is not an independent prognostic factor in high-grade glioma. J Can Res Ther [serial online] 2011 [cited 2019 Oct 18];7:331-5. Available from: http://www.cancerjournal.net/text.asp?2011/7/3/331/87039


 > Introduction Top


High-grade gliomas (HGG) are the most common primary brain tumors with a majority of the tumors presenting as localized/ focal disease. [1] For these tumors, treatment generally involves maximal safe surgical resection followed by radiation therapy and chemotherapy with a progression-free survival (PFS) of 6.9 months and overall survival (OS) of 14.6 months in a prospective phase III trial. [2] Age, histologic grade and Karnofsky performance status (KPS), among other covariates, were found to be significant in predicting outcomes in HGG based on the results of three successive Radiation Therapy Oncology Group trials that employed recursive partitioning analysis. [1]

Invasive HGG involving multiple lobes is a rare entity at presentation seen in 2-10% of patients. [3],[4],[5],[6] These tumors can vary widely in phenotype, ranging from diffuse, non-enhancing tumor to multiple, discrete, contrast-enhancing lesions. Given the low incidence of invasive HGG, there have been no prospective studies to date. However, based on existing retrospective studies, the prognosis tends to be generally poor, with a PFS of 3-4 months and OS of 7-18 months. [4],[5],[7],[8] A difference in survival appears to exist in this patient population, where patients with gliomatosis were found to have a median overall survival of 16-18 months, compared to 7-9 months in patients with multicentric tumors. [4],[5],[7],[8]

Along with increased mitosis and angiogenesis, invasion is a hallmark of HGG as with all other cancers. [9] While invasion may not be readily apparent on conventional imaging early on, it becomes more pronounced with time. [1] The autopsy studies have shown that tumor infiltration occurs up to 2 cm beyond the gross tumor in a majority of the patients. [10] In an effort to improve the outcome, anti-angiogenic therapy is being explored in the treatment of HGG, with bevacizumab (Avastin®; Genentech, South San Francisco, CA) being the most studied agent at this time. [11],[12] Despite impressive radiological responses, both in-vitro and in-vivo studies have demonstrated that bevacizumab tends to increase the incidence of diffuse invasive recurrence (DIR). [13],[14],[15] At this time, it is not clear whether invasion has any prognostic significance on HGG, whether in focal HGG or invasive HGG. The aim of this study is to look at the effect of invasiveness on survival either at the time of original diagnosis or at the time of recurrence following anti-angiogenic therapy.


 > Materials and Methods Top


Institutional review board approval was obtained for the retrospective analysis of 81 consecutive newly diagnosed HGG patients treated at New York University Langone Medical Center and Overlook Hospital from March 2006 to September 2010. All patients had either invasive HGG at initial presentation (n=23), or focal HGG at initial presentation that was treated with bevacizumab-based therapy (n=58). All patients except two with brain stem involvement underwent maximal safe surgical resection at the time of initial diagnosis. Patients with invasive HGG received radiation therapy as either involved field (IFRT) to 59.4 Gy at 1.8 Gy/fraction or whole brain (WBRT) to a dose of 40.05 Gy at 2.67 Gy/fraction. Those who were initially diagnosed with focal HGG received IFRT to a dose of 59.4 Gy at 1.8 Gy/fraction. All patients were treated with concomitant temozolomide at 75 mg/m 2 during radiation, followed by up to 12 months of treatment with temozolomide at 150 mg/m 2 given day 1-5 of 28 day cycle. Focal HGG patients received additional therapy with bevacizumab given intravenously at 10 mg/kg on days 14 and 28 during radiation therapy, and every two weeks thereafter.

Diffuse invasive disease at presentation was defined as diffuse T2 or fluid attenuated inversion recovery (FLAIR) changes with involvement of more than two lobes of brain with or without associated contrast enhancing lesions [Figure 1]. Modified MacDonald's criteria were used to determine progression, using maximal cross sectional T1 contrast-enhanced images, along with (FLAIR) sequences. [16] A 25% increase in the size of a lesion or the appearance of a new lesion defined progression. In patients with focal HGG, a diffuse invasive disease was defined as an increase in FLAIR changes with or without contrast-enhancement that involved more than two lobes with or without crossing the midline following therapy [Figure 2]. Local recurrence (LR) was defined as recurrence within a 2 cm margin of the original, primary tumor and/or confined to the lobe. All patients underwent magnetic resonance imaging (MRI) in every two months during follow-up.
Figure 1: Diffuse invasive high-grade glioma presenting as either noncontrast-enhancing (a and b) or as contrast-enhancing tumor (c and d). 1a and 1c represent T2/FLAIR images while 1b and 1d represent T1 images with gadolinium contrast

Click here to view
Figure 2: A nineteen-year-old male with anaplastic astrocytoma of right temporal lobe focal treated with surgery, radiation, temozolomide, and bevacizumab, who recurred three years later as diffuse invasive
recurrence. The slides show FLAIR images pre-treatment (a), two year post-treatment (b) and at the time of recurrence three years post treatment (c and d)


Click here to view


Kaplan-Meier estimates were used to determine the PFS and OS, and the log rank test was used to compare the survival distributions. Multivariate Cox proportional hazard models were used to determine the extent of the effect of having invasive HGG versus focal HGG in relation to known prognostic factors. Age, KPS, surgical extent, and tumor grade were considered covariates in the Cox model. Patients who were alive at the last follow-up were considered as censored events. A P-value of 0.05 was considered as statistically significant. All calculations were made using the PASW software program (Version 18; PASW Inc., Chicago IL).


 > Results Top


Patient characteristics

The patient characteristics are shown in [Table 1] for the entire patient population. The median age at the time of presentation was 54 years. The median KPS for all patients was 90. Fourteen patients with invasive HGG presented as diffuse non-contrast enhancing disease while 9 patients presented with contrast enhancing multi-centric disease. In the focal HGG group, 20 patients experienced a DIR while 16 failed as an LR. The median time to follow-up was 15.5 months.
Table 1: Patient characteristics

Click here to view


Local control

Fifty patients have experienced a recurrence at the time of analysis. The median PFS was 6 months and 11 months for patients with invasive HGG and focal HGG disease respectively (P=0.092), [Figure 3]. The median PFS for patients with focal HGG who recurred as DIR compared to those who did not was 9 months and 11 months respectively (P=0.816). In the subgroup of invasive HGG that showed significant angiogenesis, the median PFS was 3 months compared to 9 months in those who did not (P=0.088).
Figure 3: Median progression-free survival

Click here to view


Survival

Thirty-four patients have died at the time of analysis. The median OS was 13 months and 24 months for patients with invasive HGG and focal HGG, respectively (P=0.071), [Figure 4]. The median OS for patients with focal HGG who recurred as DIR compared to those who did not was 21 months versus 26 months, respectively (P=0.257). In the subgroup of invasive HGG that showed significant angiogenesis, the median OS was 9 months compared to 16 months in those who did not (P=0.145). For the entire group, the patients who showed both angiogenesis and invasion had the worst survival (P=0.006), [Figure 5].
Figure 4: Median overall survival

Click here to view
Figure 5: Median overall survival stratifi ed by patient group

Click here to view



 > Discussion Top


Diffuse invasive disease at the time of diagnosis has a wide spectrum that extends from gliomatosis cerebri with diffuse permeation, minimal contrast enhancement and near normal preservation of neural architecture to multifocal disease with contrast-enhancing lesions scattered throughout the brain in the background of underlying invasive disease. [4],[7] Such a presentation tends to compromise the extent of surgical resection as well as the volume and dose of radiation therapy. However, the impact of such a presentation on survival is not clear. The incidence of diffusive invasive disease at diagnosis is very low, and few publications exist that assess the outcome in these patients. While some small retrospective studies have shown a poor outcome, [5] others have reported outcomes that are not different from focal HGG. [7],[8] It is possible that the poor outcome may not be related to sub-optimal therapy alone and may have more to do with underlying biology that includes both angiogenesis and the invasiveness of the tumor.

These results have important implications even in the context of focal HGG, with respect to invasion. Invasion in gliomas is a complex process that involves changes in adhesion characteristics of the tumor cell, degradation of the extracellular matrix and alterations in cytoplasmic contractility that promote tumor cell motility. [17] Untreated HGG generally invades normal brain tissue by infiltrating as single cells into the brain parenchyma, migrating along basement membranes and blood vessels. [18] VEGF, a powerful stimulus that drives angiogenesis, has been shown to block invasion both in vitro and in vivo. [18] In murine glioblastomas derived from transgenic mice that lacked VEGF expression, there was promotion of invasion along blood vessels instead of through parenchyma. [19] A similar mechanism has been noted following bevacizumab therapy with tumor cells migrating as multicellular layers along normal blood vessels using them as conduits into normal tissue or infiltrate through the extracellular matrix. [19] In cases where invasion is a dominant feature at diagnosis, such as in multifocal tumors, the loss of function of p53 in particular can be linked in part to greater invasion observed in this subset due to uncontrolled activation of the proto-oncogene Ets-1. [20],[21],[22] The loss of function of p53 can also cause overexpression of HIF-1a, leading to the upregulation of VEGF and other angiogenic factors. [23],[24]

Angiogenesis with contrast enhancement as a surrogate marker is one of the most important prognostic indicators in HGG. [25],[26] While in the context of all HGG, invasion is not necessarily dominant at diagnosis, it does become dominant over time, especially in the setting of anti-angiogenic therapy. In our series as well as others, the subgroup of patients with contrast enhancement and dominant invasion pattern fared the worst. [5] We have also shown that diffuse disease at recurrence does not adversely affect survival. This indicates that invasion by itself is not an independent prognostic factor in HGG, although it potentiates the angiogenesis when present at diagnosis. Though the sample size for this study is small, given that diffuse invasive disease at diagnosis is very rare and that this was not a prospective trial, the numbers were sufficient enough to conclude that invasion is not a prognostic factor. This has an impact on the choice of anti-angiogenic agent and how potential anti-invasive compounds are introduced into therapy.

Currently cilengitide-an anti- avb3 and anti- avb5 integrin inhibitor-is being investigated for its efficacy in the treatment of both newly diagnosed and recurrent malignant gliomas. [27],[28] Lithium, which blocks glycogen sythase kinase 3, has shown the ability to block invasion in both spheroid and animal models and is being explored in a phase II clinical trial. [29] Since it is likely that after recurrence the mechanisms for invasion are already active, it may be more efficacious to introduce anti-invasive therapy at diagnosis to maximize the potential benefit.


 > Conclusion Top


The presence of diffuse invasive disease not accompanied by angiogenesis either prior to therapy or subsequent to anti-angiogenic therapy does not seem to have prognostic significance. However, invasion accompanied by angiogenesis appears to confer a poor prognosis. This has an impact on the choice and the timing of anti-angiogenic therapy used in HGG.

 
 > References Top

1.Narayana A, Recht L, Gutin PH. Central Nervous System Tumors. In: Philips TL, Hoppe R, Roach M, editors. Leibel and Philips Textbook of radiation oncology. 3 rd ed. Philadelphia: Saunders; 2010. p. 421-32.  Back to cited text no. 1
    
2.Stupp R, Mason W, Bent M, Weller M, Fisher B, Taphoorn M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.  Back to cited text no. 2
    
3.Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer 1987;60:1519-31.  Back to cited text no. 3
[PUBMED]    
4.Salvati M, Caroli E, Orlando E, Frati A, Artizzu S, Ferrante L. Multicentric glioma: Our experience in 25 patients and critical review of the literature. Neurosurg Rev 2003;26:275-9.  Back to cited text no. 4
    
5.Showalter TN, Andrel J, Andrews DW, Curran Jr WJ, Daskalakis C, Werner-Wasik M. Multifocal Glioblastoma Multiforme: Prognostic Factors and Patterns of Progression. Int J Radiat Oncol Biol Phys 2007;69:820-4.  Back to cited text no. 5
    
6.Djalilian HR, Shah MV, Hall WA. Radiographic incidence of multicentric malignant gliomas. Surg Neurol 1999;51:554-8.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH. Gliomatosis cerebri: Improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:1137-46.  Back to cited text no. 7
[PUBMED]  [FULLTEXT]  
8.Park S, Suh YL, Nam DH, Kim ST. Gliomatosis cerebri: Clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 2009;28:73-82.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Leibel SA, Levin VA, Gutin PH. Neoplasms of the Central Nervous System. 6 th ed. In: DeVita VT, Hellman S, Rosenberg SA, editors. Philadelphia: Lippincott Williams and Wilkins; 2001.  Back to cited text no. 9
    
10.Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.  Back to cited text no. 10
[PUBMED]    
11.Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010;116:3988-99.  Back to cited text no. 11
[PUBMED]  [FULLTEXT]  
12.Schneider BP, Sledge GW. Drug Insight: VEGF as a therapeutic target for breast cancer. Nat Clin Prac Oncol 2007;4:181-9.  Back to cited text no. 12
    
13.de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-42.  Back to cited text no. 13
[PUBMED]  [FULLTEXT]  
14.Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6.  Back to cited text no. 14
[PUBMED]  [FULLTEXT]  
15.Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-87.  Back to cited text no. 15
    
16.Macdonald D, Cascino T, Schold S, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.  Back to cited text no. 16
    
17.Tate MC, Aghi MK. Biology of Angiogenesis and Invasion in Glioma. Neurotherapeutics 2009;6:447-57.  Back to cited text no. 17
[PUBMED]  [FULLTEXT]  
18.Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.  Back to cited text no. 18
[PUBMED]  [FULLTEXT]  
19.Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.  Back to cited text no. 19
    
20.Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM, et al. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 2003;22:7716-27.  Back to cited text no. 20
    
21.Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, et al. Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes. Int J Oncol 2009;34:377-89.  Back to cited text no. 21
[PUBMED]  [FULLTEXT]  
22.Krex D, Mohr B, Appelt H, Schackert HK, Schackert G. Genetic analysis of a multifocal glioblastoma multiforme: A suitable tool to gain new aspects in glioma development. Neurosurgery 2003;53:1377-84.  Back to cited text no. 22
[PUBMED]  [FULLTEXT]  
23.Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L. p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription. J Biol Chem 1998;273:11995-8.  Back to cited text no. 23
[PUBMED]  [FULLTEXT]  
24.Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1a. Genes Dev 2000;14:34-44.  Back to cited text no. 24
[PUBMED]  [FULLTEXT]  
25.Chaichana KL, Kosztowski T, Niranjan A, Olivi A, Weingart JD, Laterra J, et al. Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosur 2010;113:286-92.  Back to cited text no. 25
    
26.Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR Imaging Correlates of Survival in Patients with High-Grade Gliomas. AJNR Am J Neuroradiol 2005;26:2466-74.  Back to cited text no. 26
[PUBMED]  [FULLTEXT]  
27.Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. J Clin Oncol 2008;26:5610-7.  Back to cited text no. 27
[PUBMED]  [FULLTEXT]  
28.Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, et al. Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 2010;28:2712-8.  Back to cited text no. 28
    
29.Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol 2008;10:690-9.  Back to cited text no. 29
[PUBMED]  [FULLTEXT]  


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
 
 
    Tables

  [Table 1]


This article has been cited by
1 Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience
Cabanas, R. and Saurez, G. and Rios, M. and Alert, J. and Reyes, A. and Valdes, J. and Gonzalez, M.C. and Pedrayes, J.L. and Avila, M. and Herrera, R. and Infante, M. and Echevarria, E. and Moreno, M. and Luaces, P.L. and Ramos, T.C.
mAbs. 2013; 5(2): 202-207
[Pubmed]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Materials and Me...>Results>Discussion>Conclusion>Article Figures>Article Tables
  In this article
>References

 Article Access Statistics
    Viewed3141    
    Printed167    
    Emailed1    
    PDF Downloaded265    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]